Publication: Interleukin-6: a molecule with complex biological impact in cancer
Authors
Lacina, Lukáš ; Brábek, Jan ; Král, Vladimír ; Kodet, Ondřej ; Smetana Jr, Karel
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia. Departamento de Biología Celular e Histología
publication.page.editor
publication.page.department
DOI
DOI: 10.14670/HH-18-033
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Interleukin-6 is a multifaceted cytokine,
usually reported as a pro-inflammatory molecule.
However, certain anti-inflammatory activities were also
attributed to IL-6. The levels of IL-6 in serum as well as
in other biological fluids are elevated in an agedependent manner. Notably, it is consistently reported
also as a key feature of the senescence-associated
secretory phenotype. In the elderly, this cytokine
participates in the initiation of catabolism resulting in,
e.g. sarcopenia. It can cross the blood-brain barrier, and
so it is in causal association with, e.g. depression,
bipolar disorder, schizophrenia, and anorexia. In the
cancer patient, IL-6 is produced by cancer and stromal
cells and actively participates in their crosstalk. IL-6
supports tumour growth and metastasising in terminal
patients, and it significantly engages in cancer cachexia
(including anorexia) and depression associated with
malignancy. The pharmacological treatment impairing
IL-6 signalling represents a potential mechanism of antitumour therapy targeting cancer growth, metastatic
spread, metabolic deterioration and terminal cachexia in
patients.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. CC BY 4.0